1. In vitro antibacterial activities
Cefotiam (SCE-963) showed more potent antibacterial activities against clinically isolated E. coli, K.pneumoniae and P. mirabilis than cefazolin, cephaloridine and cefmetazole. Cefotiam was, however, less active against P. vulgaris and S. marcescens than cephamycin antibiotics.
2. Experimental infections
Cefotiam was effective against experimental pneumonia caused by K. pneumoniae in mice. Daily doses of 120mg/kg divided into 3 were more effective than single daily dose of 120mg/kg.
3. Absorption and excretion
Peak serum level of 27.0μ/ml appeared at the end of lg i.v. drip infusion over 2 hours. Six-hour urinary recovery was 69%.
4. Clinical responses
Cefotiam was given to 8 patients. Responses were good in 3 patients, fair in 1, poor in 3 and unassessable in 1. No side effects were observed.
